{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:18:53Z","timestamp":1791357533009,"version":"4.3.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Introduction:<\/jats:bold>\n                    Selective serotonin reuptake inhibitors (SSRIs) are the most often used medications to treat major depressive disorder (MDD). Despite their effectiveness in reducing depressive symptoms, several issues are associated with their use in MDD, such as limited improvement of anhedonia, emergence of emotional blunting, induction or exacerbation of insomnia, and sexual dysfunction. Due to its also devoid of the issues related to treatment noted with SSRIs. The aim of this 12-week non-inferiority naturalistic observation was to compare the effectiveness and tolerability of SSRIs and trazodone in extended release (XR) in MDD.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    A total of 186 subjects were recruited, of which 92 received trazodone XR and 94 received SSRIs. Patients were allocated to trazodone XR or SSRIs, according to the attending physician based on clinical evaluation. Assessments at baseline and weeks 2, 4, 8, and 12 were conducted to evaluate the severity of depression (Montgomery\u2013\u00c5sberg Depression Rating Scale, clinician- and patient-rated Quick Inventory of Depressive Symptomatology\u2014the primary endpoints of the study), anhedonia (the Snaith\u2013Hamilton Pleasure Scale), anxiety (the Hamilton Anxiety Rating Scale), insomnia (the Athens Insomnia Scale), and therapeutic effectiveness (the Clinical Global Impression Scale).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    After 12\u00a0weeks, trazodone XR was more effective than SSRIs in reducing the severity of depression, anxiety, and insomnia. There was a trend for higher effectiveness of in reduction of anhedonia, which became insignificant after controlling the results for the duration of previous psychiatric treatment as a covariate. The proportion of treatment-responsive subjects in the trazodone XR group compared to SSRIs was comparable or higher. The proportion of patients achieving remission was higher in the trazodone XR arm vs. the SSRI arm.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Discussion:<\/jats:bold>\n                    In summary, the results indicate that trazodone XR is effective in MDD in the \u201creal-world\u201d setting. Its potential superiority over SSRIs in addressing particular symptomatic dimensions should be verified in future studies.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2023.1296639","type":"journal-article","created":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T13:15:08Z","timestamp":1698844508000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["TED\u2014trazodone effectiveness in depression: a naturalistic study of the effeciveness of trazodone in extended release formulation compared to SSRIs in patients with a major depressive disorder"],"prefix":"10.3389","volume":"14","author":[{"given":"Dominika","family":"Dudek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian Andrzej","family":"Chrobak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Julia","family":"Krupa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Gorostowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Gerlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Juryk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Siwek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"CD008581","DOI":"10.1002\/14651858.CD008581.pub2","article-title":"Antidepressants for the treatment of people with co-occurring depression and alcohol dependence","volume":"2018","author":"Agabio","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1207621","DOI":"10.3389\/fpsyt.2023.1207621","article-title":"Treating depression in clinical practice: new insights on the multidisciplinary use of trazodone","volume":"14","author":"Albert","year":"2023","journal-title":"Front. Psychiatry"},{"key":"B3","volume-title":"Clinical practice guideline for the treatment of depression across three age cohorts","year":"2019"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2147\/NDT.S185757","article-title":"Selective serotonin reuptake inhibitor-induced sexual dysfunction: current management perspectives","volume":"16","author":"Atmaca","year":"2020","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"B5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00702-019-02014-y","article-title":"Genetic endophenotypes for insomnia of major depressive disorder and treatment-induced insomnia","volume":"126","author":"Badamasi","year":"2019","journal-title":"J. Neural Transm."},{"key":"B6","first-page":"294","article-title":"Fluoxetine versus trazodone efficacy and activating sedating effects","volume":"52","author":"Beasley","year":"1991","journal-title":"J. Clin. Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1017\/S1092852917000773","article-title":"Is trazodone more effective than clomipramine in major depressed outpatients? A single-blind study with intravenous and oral administration","volume":"24","author":"Buoli","year":"2019","journal-title":"CNS Spectrums"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e1737","DOI":"10.1002\/mpr.1737","article-title":"Content overlap analysis of 64 (hypo)mania symptoms among seven common rating scales","volume":"27","author":"Chrobak","year":"2018","journal-title":"Int. J. Methods Psychiatric Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/00004714-199404000-00003","article-title":"A comparison of venlafaxine, trazodone, and placebo in major depression","volume":"14","author":"Cunningham","year":"1994","journal-title":"J. Clin. Psychopharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1708\/3202.31796","article-title":"Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: Pharmacology and clinical practice","volume":"54","author":"Cuomo","year":"2019","journal-title":"Riv. Psichiatr."},{"key":"B12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.12740\/PP\/ONLINEFIRST\/105415","article-title":"Cognitive dysfunctions in depression - significance, description and treatment prospects","volume":"54","author":"Czerwi\u0144ska","year":"2020","journal-title":"Psychiatr. Pol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1017\/S1092852920001418","article-title":"Outcome in depression (I): why symptomatic remission is not good enough","volume":"26","author":"Demyttenaere","year":"2021","journal-title":"CNS Spectrums"},{"key":"B14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1023\/A:1021137118956","article-title":"The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists","volume":"14","author":"Dording","year":"2002","journal-title":"Ann. Clin. Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/YIC.0000000000000304","article-title":"A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder","volume":"35","author":"Fagiolini","year":"2020","journal-title":"Int. Clin. Psychopharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s40263-012-0010-5","article-title":"Rediscovering trazodone for the treatment of major depressive disorder","volume":"26","author":"Fagiolini","year":"2012","journal-title":"CNS Drugs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jad.2020.11.106","article-title":"Effectiveness of vortioxetine on emotional blunting in patients with major depressive disorder with inadequate response to SSRI\/SNRI treatment","volume":"283","author":"Fagiolini","year":"2021","journal-title":"J. Affect. Disord."},{"key":"B18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12991-023-00465-y","article-title":"Role of trazodone in treatment of major depressive disorder: an update","volume":"22","author":"Fagiolini","year":"2023","journal-title":"Ann. General Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1177\/089198878900200407","article-title":"Fluoxetine versus trazodone in depressed geriatric patients","volume":"2","author":"Falk","year":"1989","journal-title":"J. Geriatric Psychiatry Neurology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jad.2016.10.019","article-title":"The 52 symptoms of major depression: lack of content overlap among seven common depression scales","volume":"208","author":"Fried","year":"2017","journal-title":"J. Affect. Disord."},{"key":"B21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jad.2013.10.002","article-title":"Duration of untreated illness and outcomes in unipolar depression: a systematic review and meta-analysis","author":"Ghio","year":"2014","journal-title":"J. Affect. Disord."},{"key":"B22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jad.2017.05.048","article-title":"Emotional blunting with antidepressant treatments: a survey among depressed patients","volume":"221","author":"Goodwin","year":"2017","journal-title":"J. Affect. Disord."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"James","year":"2018","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1185\/030079905X53243","article-title":"A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder","volume":"21","author":"Kasper","year":"2005","journal-title":"Curr. Med. Res. Opin."},{"key":"B25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.genhosppsych.2014.10.010","article-title":"Antidepressant-induced sexual dysfunction during treatment with fluoxetine, sertraline and trazodone; a randomized controlled trial","volume":"37","author":"Khazaie","year":"2015","journal-title":"General Hosp. Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/jmwh.12607","article-title":"Selective serotonin reuptake inhibitors as first-line antidepressant therapy for perinatal depression","volume":"62","author":"Latendresse","year":"2017","journal-title":"J. Midwifery Women\u2019s Health"},{"key":"B27","doi-asserted-by":"publisher","first-page":"6699028","DOI":"10.1155\/2021\/6699028","article-title":"Use of antidepressants among patients diagnosed with depression: a scoping review","volume":"2021","author":"Marasine","year":"2021","journal-title":"BioMed Res. Int."},{"key":"B28","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jaac.2012.01.011","article-title":"Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression","volume":"51","author":"McMakin","year":"2012","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1185\/030079906X121039","article-title":"A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder","volume":"22","author":"Munizza","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"key":"B30","volume-title":"Depression in adults: screening, treatment and management","year":"2022"},{"key":"B31","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.eurpsy.2007.01.1220","article-title":"A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder","volume":"22","author":"Papakostas","year":"2007","journal-title":"Eur. Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/pra.0000000000000082","article-title":"How commonly used inclusion and exclusion criteria in antidepressant registration trials affect study enrollment","volume":"21","author":"Preskorn","year":"2015","journal-title":"J. Psychiatric Pract."},{"key":"B33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1192\/bjp.bp.108.051110","article-title":"Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study","volume":"195","author":"Price","year":"2009","journal-title":"Br. J. Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.7326\/M22-2056","article-title":"Nonpharmacologic and pharmacologic treatments of adults in the acute phase of major depressive disorder: a living clinical guideline from the American college of physicians","volume":"176","author":"Qaseem","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"B35","volume-title":"A language and environment for statistical computing","year":"2022"},{"key":"B36","doi-asserted-by":"publisher","first-page":"235","DOI":"10.12740\/PP\/ONLINEFIRST\/132496","article-title":"Pharmacological treatment of a depressive episode and recurrent depressive disorder \u2013 guidelines of the polish psychiatric association and the national consultant for adult Psychiatry","volume":"55","author":"Samochowiec","year":"2021","journal-title":"Psychiatr. Pol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"216","DOI":"10.15557\/PiPK.2017.0026","article-title":"Anhedonia in\u00a0depressive disorders","volume":"17","author":"Siwek","year":"2017","journal-title":"Psychiatr. i Psychol. Klin."},{"key":"B38","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3390\/brainsci13010086","article-title":"TED\u2014trazodone efficacy in depression: a naturalistic study on the efficacy of trazodone in an extended-release formulation compared to SSRIs in patients with a depressive episode\u2014preliminary report","volume":"13","author":"Siwek","year":"2023","journal-title":"Brain Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/da.21993","article-title":"Self-report and clinician-rated measures of depression severity: can one replace the other?","volume":"29","author":"Uher","year":"2012","journal-title":"Depress. Anxiety"},{"key":"B41","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/13651500600552594","article-title":"Sleep problems in depression: how do they impact treatment and recovery?","volume":"10","author":"Wade","year":"2006","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"B42","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3109\/13651501.2015.1031139","article-title":"Anhedonia in depressed patients on treatment with selective serotonin reuptake inhibitor anti-depressant - a two-centered study in Malaysia","volume":"19","author":"Yee","year":"2015","journal-title":"Int. J. Psychiatry Clin. Pract."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1296639\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T13:16:15Z","timestamp":1698844575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1296639\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":42,"alternative-id":["10.3389\/fphar.2023.1296639"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1296639","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,1]]},"article-number":"1296639"}}